Open Access. Powered by Scholars. Published by Universities.®
Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- 3rd level students (1)
- AHUS (1)
- Anaemia (1)
- Anaphylaxis (1)
- Aspirin (1)
-
- BRCA (1)
- COVID-19 (1)
- CTTP (1)
- Cancer (1)
- Checkpoint inhibitors (1)
- Coagulopathy (1)
- Coronavirus (1)
- Cytokine storm (1)
- DHUS (1)
- Diabetes (1)
- Dialysis (1)
- Dietetic service (1)
- Eculizumab (1)
- Emicizumab-kxwh (1)
- FVIII (1)
- Fetal RHD Screening (1)
- Food allergen (1)
- Food allergy (1)
- Gene (1)
- Genetic screening (1)
- Haemolysis (1)
- Haemolytic Disease of the Fetus/Newborn (1)
- Haemophilia A (1)
- Health sciences (1)
- Hyperglycaemia (1)
Articles 1 - 3 of 3
Full-Text Articles in Congenital, Hereditary, and Neonatal Diseases and Abnormalities
An Assessment Of Fetal Rhd Screening In Non-Invasive Prenatal Testing (Nipt) And Implementation Of Targeted Routine Antenatal Anti-D Prophylaxis (Traadp) In Enhancing Management Of Rhd-Negative Women At Risk Of Haemolytic Disease Of The Fetus/Newborn (Hdfn) In University Hospital Limerick Group (Uhlg), Anna Pohrebyannyk
International Undergraduate Journal of Health Sciences
Alloimmunisation, formerly isoimmunisation, or sensitisation can occur in pregnancy when a Rhesus D (RhD)-negative woman carries an RhD-positive fetus. Incompatibility of Rh status causes development of allo anti-D antibodies in response to antigen exposure from foreign fetal red cells in fetomaternal haemorrhages (FMHs) or potential sensitising events (PSEs) i.e., iatrogenic interventions (medical or surgical treatment), silent or spontaneous transplacental haemorrhages (STHs) in pregnancy, at birth or other traumas. Anti-D antibodies are immune-mediated and can cross the placenta and attach to fetal cells causing destruction and haemolysis. Offspring of primigravida women are unaffected usually and it is later pregnancies that may …
Emicizumab-Kxwh: A Critical Review, Kiera O'Leary
Emicizumab-Kxwh: A Critical Review, Kiera O'Leary
International Undergraduate Journal of Health Sciences
The first descriptions of haemophilia A were reported in the second century AD, with the first modern description by John Conrad Otto in 1803. Historically, the natural history of haemophilia A was associated with very high rates morbidity and mortality, often following trivial accidents. Although treatment options for haemophilia A have been revolutionised in recent decades, haemophilia A remains a hereditary disease of concern and factor replacement products remain the mainstay of treatment.
As such, patients with haemophilia can carry huge burdens, particularly when a complication such as a FVIII inhibitor is present. A recently approved novel therapeutic, Emicizumab-kxwh, has …
Full Issue: The International Undergraduate Journal Of Health Sciences, Volume 1, Issue 1, June 2021
Full Issue: The International Undergraduate Journal Of Health Sciences, Volume 1, Issue 1, June 2021
International Undergraduate Journal of Health Sciences
The full June 2021 issue (Volume 1, Issue 1) of the International Undergraduate Journal of Health Sciences